Rehovot-based Rosetta Genomics Ltd. (Nasdaq: ROSG) has announced a collaboration agreement with the Henry Ford Health System in Detroit, Michigan, to develop microRNA-based diagnostics and prognostics for brain cancer. The Henry Ford Hospital is one of the world's leading research centers for brain cancer. Rosetta Genomics specializes in the development of microRNA-based diagnostics and therapeutics.
The parties will conduct a genome-wide molecular analysis of human brain cancer tumors to identify unique microRNA biomarkers that have diagnostic and prognostic potential. Upon receipt of the results from this analysis, Rosetta Genomics will use its proprietary microRNA extraction technologies to perform a microRNA analysis from Formalin Fixed Paraffin Embedded (FFPE) samples received from Henry Ford Hospital.
"The goal of our collaborations with the leading cancer research centers is to seek new indications for our microRNA-based diagnostics," said Rosetta Genomics president and CEO Amir Avniel. Together with Henry Ford Hopsital's leading brain cancer researchers, we believe we will be able to leverage the potential microRNAs hold as biomarkers to develop diagnostic and prognostic tools for this difficult disease."
"There is great unmet medical need for improved diagnostics in identifying and treating patients with brain cancer," said Chaya Brodie, Ph.D., and Tom Mikkelsen, M.D. of the department of neurosurgery at Henry Ford Hospital. Combining Rosetta Genomics' proprietary technologies for microRNA research and its experience in this field with our expertise in brain cancer is a good starting point for this important project."
Published by Globes [online], Israel business news - www.globes.co.il - on January 15, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008